The Motley Fool
13 Jun 2026, 22:15 UTC · 3h ago
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
13 Jun 2026, 22:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Bristol Myers Squibb faces upcoming patent losses for key drugs including Revlimid, Pomalyst, and Eliquis. — Patent expirations create material pressure on top and bottom line revenue, posing a direct risk to earnings growth.
-0.60Bristol Myers Squibb maintains an investment-grade credit rating with a decreasing debt-to-equity ratio (from 3x to 2.2x). — Strong balance sheet health and improved leverage reduce solvency risk and provide a cushion to maintain dividends during revenue transitions.
+0.40The company's dividend payout ratio is approximately 72%. — A high payout ratio leaves less room for error if earnings decline due to the aforementioned patent losses.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Bristol Myers Squibb is currently offering a dividend yield of approximately 4.5%. — A yield significantly higher than the S&P 500 and sector average makes the stock more attractive to income-seeking investors.
Which stocks this story touches
The company offers an attractive yield and strong balance sheet, despite facing headwinds from patent expirations.
Mentioned only as a marketing partner for Eliquis without specific positive or negative commentary on its own fundamentals.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
6h ago
